

Christopher Filson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6312204/publications.pdf>

Version: 2024-02-01

145
papers

2,645
citations

236612

25
h-index

205818

48
g-index

147
all docs

147
docs citations

147
times ranked

4985
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	2.0	3
2	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.2	3
3	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.2	13
4	Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 80-89.	0.2	2
5	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. <i>Prostate</i> , 2022, 82, 876-879.	1.2	2
6	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	1.3	3
7	Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. <i>Cancer</i> , 2022, 128, 3287-3296.	2.0	13
8	Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 432.e1-432.e10.	0.8	23
9	Decision support for men with prostate cancer: Concordance between treatment choice and tumor risk. <i>Cancer</i> , 2021, 127, 203-208.	2.0	2
10	Reply to What is a good medical choice?. <i>Cancer</i> , 2021, 127, 1935-1936.	2.0	0
11	Enhanced antibiotic prophylaxis and infection-related complications following prostate biopsy. <i>World Journal of Urology</i> , 2021, 39, 3415-3422.	1.2	1
12	Editorial Comment. <i>Journal of Urology</i> , 2021, 205, 1359-1359.	0.2	0
13	Palliative care use among bladder cancer patients treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 788.e1-788.e6.	0.8	3
14	Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. <i>Cancer</i> , 2021, 127, 2974-2979.	2.0	6
15	The value of new drugs for advanced prostate cancer. <i>Cancer</i> , 2021, 127, 3457-3465.	2.0	6
16	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e193-e199.	0.9	1
17	Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 493.e9-493.e15.	0.8	12
18	Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 58.e9-58.e9.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. <i>Urology Practice</i> , 2021, 8, 576-582.	0.2	1
20	Longitudinal impact of bladder cancer diagnosis on common psychiatric disorders. <i>Cancer Medicine</i> , 2021, 10, 8412-8420.	1.3	4
21	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	2.6	24
22	Survival benefit with extended lymphadenectomy for advanced renal malignancy: A population-based analysis. <i>Asian Journal of Urology</i> , 2020, 7, 29-36.	0.5	4
23	Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance. <i>European Urology Focus</i> , 2020, 6, 242-248.	1.6	7
24	Payments and Patient Cost Sharing for Prostate Biopsies According to Image Guidance, Practice Site and Use of Anesthesia. <i>Urology Practice</i> , 2020, 7, 138-144.	0.2	4
25	Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening. <i>Cancer</i> , 2020, 126, 694-696.	2.0	9
26	Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer. <i>Brachytherapy</i> , 2020, 19, 557-566.	0.2	1
27	In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. <i>Radiology Imaging Cancer</i> , 2020, 2, e190078.	0.7	6
28	Effect of a Prostate Cancer Screening Decision Aid for African-American Men in Primary Care Settings. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2157-2164.	1.1	5
29	Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020, 3, e2015198.	2.8	4
30	Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2020, 141, 101-107.	0.5	4
31	Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself. <i>Cancer</i> , 2020, 126, 2322-2323.	2.0	0
32	Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States. <i>Urology</i> , 2020, 142, 87-93.	0.5	5
33	Efficacy of Percutaneous Tibial Nerve Stimulation for Overactive Bladder in Women and Men at a Safety Net Hospital. <i>Journal of Urology</i> , 2020, 203, 385-391.	0.2	7
34	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. <i>Journal of Urology</i> , 2020, 203, 727-733.	0.2	30
35	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. <i>Journal of Urology</i> , 2020, 204, 701-706.	0.2	19
36	Editorial Comment. <i>Journal of Urology</i> , 2020, 203, 135-135.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 391-391.	0.2	0
38	Antibiotic Stewardship for Ambulatory Urological Procedures: Cystoscopy and Vasectomy. <i>Urology Practice</i> , 2020, 7, 272-278.	0.2	1
39	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 36-41.	0.6	41
40	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	0.9	18
41	Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries. <i>JAMA Network Open</i> , 2019, 2, e198956.	2.8	11
42	Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 6.	1.5	12
43	Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e494-e504.	0.9	4
44	Use of Office Versus Ambulatory Surgery Center Setting and Associated Ancillary Services on Healthcare Cost Burden for Vasectomy Procedures. <i>Urology</i> , 2019, 129, 29-34.	0.5	4
45	Increasing Utilization of Multiparametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. <i>Urology</i> , 2019, 130, 99-105.	0.5	29
46	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019, 2, 333-336.	2.6	8
47	In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. <i>Radiology Imaging Cancer</i> , 2019, 1, e190016.	0.7	1
48	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019, 576, 465-470.	13.7	510
49	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	0.9	58
50	Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 181.e15-181.e21.	0.8	6
51	Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. <i>Urology Practice</i> , 2019, 6, 93-99.	0.2	7
52	Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. <i>Urology Practice</i> , 2019, 6, 123-128.	0.2	1
53	A randomized, controlled trial for transurethral treatment of bladder tumors using PlasmaButton vaporization electrode or monopolar loop electrocautery. <i>Canadian Journal of Urology</i> , 2019, 26, 9908-9915.	0.0	0
54	Risk of Readmission After Uncomplicated Hospitalization After Radical Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e705-e710.	0.9	11

#	ARTICLE	IF	CITATIONS
55	Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. <i>Urology</i> , 2018, 117, 57-63.	0.5	43
56	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. <i>Cancer</i> , 2018, 124, 2897-2905.	2.0	6
57	Editorial Comment. <i>Urology</i> , 2018, 111, 84-85.	0.5	0
58	In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? a pilot test-retest reliability study. <i>British Journal of Radiology</i> , 2018, 91, 20170603.	1.0	3
59	Physician Reimbursement for Prostate Biopsies Falls as Procedures Shift From Offices to Facilities. <i>Urology</i> , 2018, 115, 96-101.	0.5	1
60	Patient Acceptance of Teleurology via Telephone vs Face-to-Face Clinic Visits for Hematuria Consultation at a Veterans Affairs Medical Center. <i>Urology Practice</i> , 2018, 5, 253-259.	0.2	6
61	Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. <i>Journal of Urology</i> , 2018, 199, 89-97.	0.2	34
62	Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics. <i>Urology</i> , 2018, 113, 40-44.	0.5	37
63	Lymphadenectomy for High-Risk Prostate Cancer Patients: What Is Going on in Georgia?. <i>Journal of the American College of Surgeons</i> , 2018, 227, S281-S282.	0.2	0
64	Quality of care and economic considerations of active surveillance of men with prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 203-213.	0.6	2
65	High Preoperative Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in Localized and Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the American College of Surgeons</i> , 2018, 227, e243.	0.2	0
66	Moving toward a more rational, evidence-based approach to PSA screening, diagnosis, and treatment of prostate cancer. <i>Cancer</i> , 2018, 124, 2684-2686.	2.0	1
67	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 368-368.	0.2	0
68	Editorial Comment. <i>Journal of Urology</i> , 2018, 200, 59-59.	0.2	0
69	Association Between Online Information-Seeking and Adherence to Guidelines for Breast and Prostate Cancer Screening. <i>Preventing Chronic Disease</i> , 2018, 15, E45.	1.7	6
70	Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 250-256.	0.8	15
71	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 625-626.	0.2	0
72	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 689-689.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Editorial Comment. Urology, 2017, 99, 82.	0.5	0
74	Health status and use of partial nephrectomy in older adults with early-stage kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 153.e7-153.e14.	0.8	17
75	Surgical Margins in Nephron-Sparing Surgery for Renal Cell Carcinoma. Current Urology Reports, 2017, 18, 8.	1.0	39
76	Patient Frailty and Discharge Disposition Following Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e615-e621.	0.9	50
77	Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines. Journal of Urology, 2017, 198, 1046-1053.	0.2	6
78	Semantics in active surveillance for men with localized prostate cancer – results of a modified Delphi consensus procedure. Nature Reviews Urology, 2017, 14, 312-322.	1.9	65
79	PD06-03 PERSONALIZED DECISION SUPPORT FOR LOCALIZED PROSTATE CANCER: RESULTS OF A MULTI-SITE RANDOMIZED TRIAL. Journal of Urology, 2017, 197, .	0.2	0
80	MP32-01 PROSTATE BIOPSY PAYMENTS TO AMBULATORY SURGERY CENTERS STABLE AS PHYSICIAN REIMBURSEMENT FALLS: SUMMARY OF MEDICARE REIMBURSEMENT 2012 – 2014. Journal of Urology, 2017, 197, .	0.2	0
81	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. Asian Journal of Urology, 2017, 4, 230-238.	0.5	13
82	MP76-01 SHARP DECREASE IN PROSTATE BIOPSY INCIDENCE WITH WIDE GEOGRAPHIC VARIATION FOLLOWING TASK FORCE PROSTATE CANCER SCREENING RECOMMENDATIONS. Journal of Urology, 2017, 197, .	0.2	0
83	MP86-04 NEW-ONSET DEPRESSION AND MENTAL HEALTH-RELATED QUALITY OF LIFE FOLLOWING PROSTATE CANCER DIAGNOSIS WITHOUT TREATMENT. Journal of Urology, 2017, 197, .	0.2	0
84	PD18-03 LONG-TERM HEALTH RELATED QUALITY OF LIFE IN PROSTATE CANCER PATIENTS REQUIRING RADIOTHERAPY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.2	0
85	MP69-18 A PATIENT-CENTERED PRACTICE CHANGE: FINDING THE BEST APPROACH FOR PROSTATE CANCER DECISION SUPPORT. Journal of Urology, 2017, 197, .	0.2	0
86	MP08-09 POPULATION-LEVEL CANCER DETECTION AND PATTERNS OF CARE FOLLOWING MRI-GUIDED PROSTATE BIOPSY. Journal of Urology, 2017, 197, .	0.2	0
87	MP21-09 PROLONGED LENGTH OF STAY NOT ASSOCIATED WITH DECREASED HOSPITAL READMISSIONS FOLLOWING UNCOMPLICATED HOSPITALIZATION AFTER RADICAL CYSTECTOMY. Journal of Urology, 2017, 197, .	0.2	0
88	MP16-09 REEXAMINING THE ROLE OF EXTENDED LYMPHADENECTOMY FOR THE MANAGEMENT OF RENAL MALIGNANCY IN THE TARGETED THERAPY ERA. Journal of Urology, 2017, 197, .	0.2	0
89	Urologist Use of Cystoscopy for Patients Presenting With Hematuria in the United States. Urology, 2017, 100, 20-26.	0.5	17
90	Editorial Comment. Journal of Urology, 2016, 196, 1421-1421.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Prostate cancer detection with magnetic resonanceâ€”ultrasound fusion biopsy: The role of systematic and targeted biopsies. <i>Cancer</i> , 2016, 122, 884-892.	2.0	346
92	The importance of surgical margins in renal cell and urothelial carcinomas. <i>Journal of Surgical Oncology</i> , 2016, 113, 316-322.	0.8	7
93	Determinants of radical cystectomy operative time. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 431.e17-431.e24.	0.8	14
94	Expectant management of veterans with earlyâ€”stage prostate cancer. <i>Cancer</i> , 2016, 122, 626-633.	2.0	10
95	MP78-18 THE RELATIONSHIP BETWEEN PREOPERATIVE C - REACTIVE PROTEIN AND FUHRMAN NUCLEAR GRADE IN STAGE T1 RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	1
96	MP31-09 COMORBIDITY, DISABILITY, AND PARTIAL NEPHRECTOMY USE FOR OLDER PATIENTS WITH STAGE I KIDNEY CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
97	MP31-07 TELE-UROLOGY VERSUS FACE-TO-FACE CLINICS: A SURVEY OF PATIENT PREFERENCE. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
98	MP73-18 EXTERNAL VALIDATION OF PREOPERATIVE AST/ALT (DE-RITIS) RATIO AS A PROGNOSTIC INDICATOR IN LOCALIZED AND METASTATIC RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
99	The Cost Burden of Complications after Major Surgery for Urological Cancer: Opportunities for Value Creation in Urology. <i>Urology Practice</i> , 2016, 3, 81-89.	0.2	5
100	Caveat Emptor â€” long-term outcomes in the GÃ¶teborg active surveillance cohort. <i>Nature Reviews Urology</i> , 2016, 13, 307-308.	1.9	0
101	Author Reply. <i>Urology</i> , 2016, 97, 38-39.	0.5	1
102	Patient-Reported Convalescence and Quality of Life Recovery. <i>Surgical Innovation</i> , 2016, 23, 598-605.	0.4	11
103	Implementation of a Tele-urology Program for Outpatient Hematuria Referrals: Initial Results and Patient Satisfaction. <i>Urology</i> , 2016, 97, 33-39.	0.5	41
104	Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. <i>Cancer</i> , 2016, 122, 3075-3086.	2.0	254
105	MP37-06 DELAYED TREATMENT OF HIGH-RISK PROSTATE CANCER PATIENTS: IMPACT OF SOCIOECONOMIC BARRIERS AND USE OF ADVANCED TECHNOLOGIES. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
106	MP37-16 UROLOGIST USE OF CYSTOSCOPY FOR PATIENTS PRESENTING WITH HEMATURIA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
107	The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 1724-1730.	0.2	69
108	Collecting Duct Carcinoma and Renal Medullary Carcinoma. , 2016, , 109-123.		0

#	ARTICLE	IF	CITATIONS
109	PD30-01 MR-US FUSION BIOPSY TO DIAGNOSE PROSTATE CANCER: FIRST 1000 MEN AT UCLA. Journal of Urology, 2015, 193, .	0.2	0
110	MP27-15 INTOLERANCE OF UNCERTAINTY AND URINARY SYMPTOMS PREDICT ANXIETY FOR MEN ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	0
111	MP65-20 DETERMINANTS OF OPERATIVE TIME FOR BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY. Journal of Urology, 2015, 193, .	0.2	0
112	MP11-05 MR-US FUSION BIOPSY: IMPORTANCE OF BOTH SYSTEMATIC AND TARGETED SAMPLING TO DIAGNOSE PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.2	1
113	Expectant management for men with early stage prostate cancer. Ca-A Cancer Journal for Clinicians, 2015, 65, 264-282.	157.7	59
114	MP60-11 SHOULD A NORMAL MULTIPARAMETRIC MRI PRECLUDE PROSTATE BIOPSY?. Journal of Urology, 2015, 193, .	0.2	8
115	MP24-01 SECOND PRIMARY MALIGNANCIES: AN ANALYSIS OF SEER DATA. Journal of Urology, 2015, 193, .	0.2	0
116	Contemporary, age-based trends in the incidence and management of patients with early-stage kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e19-21.e26.	0.8	26
117	Logic Regression for Provider Effects on Kidney Cancer Treatment Delivery. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-9.	0.7	5
118	MP58-15 VARIATION IN USE OF ACTIVE SURVEILLANCE AMONG MEN UNDERGOING EXPECTANT MANAGEMENT OF EARLY-STAGE PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.2	0
119	Variation in Use of Active Surveillance among Men Undergoing Expectant Treatment for Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 75-81.	0.2	59
120	Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 952-957.	0.8	33
121	Improvement in Clinical TNM Staging Documentation Within a Prostate Cancer Quality Improvement Collaborative. Urology, 2014, 83, 781-787.	0.5	21
122	Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 40.e1-40.e8.	0.8	27
123	V6-06 USE OF MRI/US FUSION FOR TARGETED PROSTATE BIOPSY IN ACTIVE SURVEILLANCE. Journal of Urology, 2014, 191, .	0.2	1
124	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 27.e15-27.e21.	0.8	8
125	Technique and Outcomes of Robot-assisted Retroperitoneoscopic Partial Nephrectomy: A Multicenter Study. European Urology, 2014, 66, 542-549.	0.9	62
126	Trends in Medical Management of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia. Urology, 2013, 82, 1386-1393.	0.5	37

#	ARTICLE	IF	CITATIONS
127	143 TRENDS AND VARIATION IN MEDICAL MANAGEMENT OF MEN WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS (1993-2010). <i>Journal of Urology</i> , 2013, 189, .	0.2	0
128	Editorial Comment. <i>Urology</i> , 2013, 82, 333-334.	0.5	0
129	The Efficacy and Safety of Combined Therapy with α -Blockers and Anticholinergics for Men with Benign Prostatic Hyperplasia: A Meta-Analysis. <i>Journal of Urology</i> , 2013, 190, 2153-2160.	0.2	50
130	441 PATIENT RECOVERY AND QUALITY OF LIFE AFTER RADICAL CYSTECTOMY: COMPARISON OF OPEN VERSUS ROBOTIC APPROACHES. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
131	Prospective Tracking of Pediatric Urology Consults: Knowing is Half the Battle. <i>Journal of Urology</i> , 2012, 187, 1844-1849.	0.2	6
132	Surgical approach and the use of lymphadenectomy and adrenalectomy among patients undergoing radical nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 856-863.	0.8	15
133	1674 RISK OF COMPLICATIONS OF PERIOPERATIVE MITOMYCIN (MMC) AMONG BLADDER CANCER PATIENTS UNDERGOING ENDOSCOPIC TUMOR RESECTION. <i>Journal of Urology</i> , 2012, 187, .	0.2	1
134	319 PAYMENTS FOR OUTPATIENT UROLOGIC CARE IN NON-HOSPITAL-BASED SETTINGS. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
135	40 DO SHORT-TERM OUTCOMES FOLLOWING COMMON UROLOGIC PROCEDURES VARY BY THE AMBULATORY CARE SETTING WHERE THEY WERE PERFORMED?. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
136	Surgeon Characteristics and Long-Term Trends in the Adoption of Laparoscopic Radical Nephrectomy. <i>Journal of Urology</i> , 2011, 185, 2072-2077.	0.2	25
137	Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma. <i>Urology</i> , 2011, 77, 825-830.e1.	0.5	17
138	Health care reform in 2010: transforming the delivery system to improve quality of care. <i>World Journal of Urology</i> , 2011, 29, 85-90.	1.2	22
139	Role of biochemical markers in testicular cancer: diagnosis, staging, and surveillance. <i>Open Access Journal of Urology</i> , 2011, 4, 1.	0.3	48
140	489 USE OF PARTIAL NEPHRECTOMY IN RURAL VERSUS URBAN PRACTICE SETTINGS. <i>Journal of Urology</i> , 2010, 183, .	0.2	1
141	345 SHORT-TERM AND OFF-LABEL USE OF ORAL TARGETED THERAPY FOR PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
142	721 SURGICAL APPROACH AND THE USE OF LYMPHADENECTOMY AND ADRENALECTOMY FOR PATIENTS WITH RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
143	1481 UTILIZATION OF NEPHRON-SPARING SURGERY AMONG RENAL CELL CARCINOMA PATIENTS WITH DIABETES OR HYPERTENSION. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
144	Comparing performance of Morbidity and Mortality Conference and National Surgical Quality Improvement Program for detection of complications after urologic surgery. <i>Urology</i> , 2006, 68, 931-937.	0.5	43

#	ARTICLE	IF	CITATIONS
145	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. Journal of Urology, 0, , .	0.2	1